Vericel CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

26 Feb 2026

VCEL

10-K: Vericel Reports Strong 2025 Growth, Driven by MACI and NexoBrid

Vericel Corporation achieved significant revenue and net income growth in 2025, fueled by strong MACI sales and NexoBrid expansion, while advancing its product pipeline.

NASDAQ

27 Feb 2025

VCEL

Vericel CORP

10-K: Vericel Reports Profitable 2024, Driven by MACI and Strategic Growth Initiatives

Vericel Corporation achieves profitability in 2024, fueled by strong MACI performance and strategic expansion in sports medicine and burn care markets.

NASDAQ

29 Feb 2024

VCEL

Vericel CORP

10-K: Vericel Corporation Files 10-K, Reports on Financials and Operations for 2023

Vericel Corporation's 10-K filing details its 2023 financial performance, product portfolio, and strategic outlook, highlighting growth in MACI sales and the launch of NexoBrid.